EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Insights Into Gut Barrier Dysfunction and Metabolic Alterations in Mycophenolate‐Induced Enteropathy

Clarisse Brossier, François-Ludovic Sauvage, Christel Valencia-Schmitt, Valérie Calco, Pascal Villa, Pierre Marquet iD, Roland Lawson iD

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70204 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, 2026. Written by Clarisse Brossier and 6 co-authors. Institution: INSERM, Univ. Limoges, Pharmacology & Transplantation, U1248, Limoges, France. Major MEDLINE topics: Mycophenolic Acid, Immunosuppressive Agents, Intestinal Mucosa, Intestinal Diseases. 44 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Mycophenolic acid (MPA) is a widely used immunosuppressant whose use is often limited by gastrointestinal toxicity. Gut bacterial hydrolysis of liver‐derived MPA glucuronides increases local exposure to MPA, potentially impairing epithelial barrier function and cellular metabolism. To explore the effects of MPA on gut barrier integrity and metabolic pathways in gut epithelial cells, Caco‐2 cells were exposed to MPA (10 or 100 μM), and barrier function was assessed by transepithelial electrical resistance (TEER) and lucifer yellow (LY) permeability in both differentiated and early‐stage monolayers, while intracellular metabolic changes were investigated using targeted LC–MS/MS metabolomics. In differentiated monolayers, MPA did not significantly alter LY transport or TEER measurements. In contrast, MPA exposure during the early stages of monolayer formation reduced TEER values, 3 days after MPA withdrawal (Day 6; p < 0.01). The effects of 100‐μM MPA were still noticeable at Day 10, as confirmed by LY permeability ( p < 0.05). Metabolomic profiling clearly separated exposed from control cells (PCA, PC1 + PC2 = 92% variance). At 10 and 100 μM, 9 and 8 metabolites were significantly altered, with 6 common to both doses. Pathway enrichment revealed perturbations mainly in nucleotide synthesis, consistent with altered metabolic activity.

Subjects

MeSH terms (MEDLINE)

Mycophenolic AcidImmunosuppressive AgentsIntestinal MucosaIntestinal DiseasesHumansIntestinal Barrier FunctionCaco-2 CellsPermeabilityMetabolomicsElectric ImpedanceTandem Mass SpectrometryIsoquinolines

Author keywords

Caco‐2 cellsMPA‐induced enteropathygut epithelial barrierlucifer yellowmycophenolic acid (MPA)targeted metabolomicstransepithelial electrical resistance

Substances

Mycophenolic AcidImmunosuppressive Agentslucifer yellowIsoquinolines

Authors and institutions

  • INSERM, Univ. Limoges, Pharmacology & Transplantation, U1248, Limoges, France.
  • Strasbourg Integrative Biological Chemistry Platform (PCBIS), UAR 3286 CNRS-University of Strasbourg, Strasbourg Institute for drug discovery and development (IMS), Illkirch, France.

ORCID profiles: Pierre Marquet, Roland Lawson

Cite

APA

Brossier, C., Sauvage, F. L., Valencia-Schmitt, C., Calco, V., Villa, P., Marquet, P., & Lawson, R. (2026). Insights Into Gut Barrier Dysfunction and Metabolic Alterations in Mycophenolate‐Induced Enteropathy. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70204

Vancouver

Brossier C, Sauvage FL, Valencia-Schmitt C, Calco V, Villa P, Marquet P, et al. Insights Into Gut Barrier Dysfunction and Metabolic Alterations in Mycophenolate‐Induced Enteropathy. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70204

BibTeX
@article{Brossier2026,
  author = {Brossier, Clarisse and Sauvage, François-Ludovic and Valencia-Schmitt, Christel and Calco, Valérie and Villa, Pascal and Marquet, Pierre and Lawson, Roland},
  title = {Insights Into Gut Barrier Dysfunction and Metabolic Alterations in Mycophenolate‐Induced Enteropathy},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70204}
}
Start for free →